Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03165409 · ClinicalTrials.gov registry record
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,828
- Enrollment target
NCT03165409: Completed study, sponsored by Bristol-Myers Squibb.
NCT03165409 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,828 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03165409 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,828 participants
- Enrollment target
Study Summary
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,828 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2017-09-30 |
What the finished NCT03165409 record still lists
NCT03165409 is an observational study that tracks outcomes without assigning an intervention. Its 1,828 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03165409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03165409 about?
NCT03165409 is a clinical study titled "Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread". This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
What is the current status of trial NCT03165409?
This trial is currently completed. The enrollment target is 1,828 participants. The study started on 2017-02-27. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT03165409?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03165409?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI